{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:38:54Z","timestamp":1791329934197,"version":"4.3.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s40261-018-0692-7","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T04:16:00Z","timestamp":1535688960000},"page":"1001-1009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin"],"prefix":"10.1007","volume":"38","author":[{"given":"Kenneth","family":"Duchin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Senaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vance","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Marbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Lasseter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2501-5669","authenticated-orcid":false,"given":"Hamim","family":"Zahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"key":"692_CR1","doi-asserted-by":"crossref","unstructured":"Yokoyama T, Arakawa N, Domon Y, Matsuda F, Inoue T, Kitano Y, et al. Pharmacological, pharmacokinetics and safety profiles of DS-5565, a novel \u03b12\u03b4 ligand. Neurology. 2014;82 (10 Supplement)\u00a0P7.301.","DOI":"10.1016\/j.jns.2013.07.1884"},{"issue":"13","key":"692_CR2","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1523\/JNEUROSCI.0356-09.2009","volume":"29","author":"CS Bauer","year":"2009","unstructured":"Bauer CS, Nieto-Rostro M, Rahman W, Tran-Van-Minh A, Ferron L, Douglas L, et al. The increased trafficking of the calcium channel subunit \u03b12\u03b4-1 to presynaptic terminals in neuropathic pain is inhibited by the \u03b12\u03b4 ligand pregabalin. J Neurosci. 2009;29(13):4076\u201388. https:\/\/doi.org\/10.1523\/JNEUROSCI.0356-09.2009 .","journal-title":"J Neurosci"},{"issue":"1\u20132","key":"692_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pain.2006.04.022","volume":"125","author":"CY Li","year":"2006","unstructured":"Li CY, Zhang XL, Matthews EA, Li KW, Kurwa A, Boroujerdi A, et al. Calcium channel \u03b12\u03b41 subunit mediates spinal hyperexcitability in pain modulation. Pain. 2006;125(1\u20132):20\u201334. https:\/\/doi.org\/10.1016\/j.pain.2006.04.022 .","journal-title":"Pain"},{"issue":"46","key":"692_CR4","doi-asserted-by":"publisher","first-page":"17537","DOI":"10.1073\/pnas.0409066103","volume":"103","author":"MJ Field","year":"2006","unstructured":"Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su TZ, et al. Identification of the \u03b12-\u03b4-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA. 2006;103(46):17537\u201342. https:\/\/doi.org\/10.1073\/pnas.0409066103 .","journal-title":"Proc Natl Acad Sci USA."},{"issue":"10","key":"692_CR5","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1074\/jbc.271.10.5768","volume":"271","author":"NS Gee","year":"1996","unstructured":"Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the \u03b12\u03b4 subunit of a calcium channel. J Biol Chem. 1996;271(10):5768\u201376.","journal-title":"J Biol Chem"},{"issue":"9","key":"692_CR6","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.2337\/dc12-1964","volume":"36","author":"S Tesfaye","year":"2013","unstructured":"Tesfaye S, Boulton AJ, Dickenson AH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care. 2013;36(9):2456\u201365. https:\/\/doi.org\/10.2337\/dc12-1964 .","journal-title":"Diabetes Care"},{"issue":"12","key":"692_CR7","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.2337\/dc14-1044","volume":"37","author":"Aaron Vinik","year":"2014","unstructured":"Vinik A, Rosenstock J, Sharma U, Feins K, Hsu C, Merante D; DS5565-A-U201 US Phase II Study Investigators. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014;37(12):3253\u201361. https:\/\/doi.org\/10.2337\/dc14-1044 .","journal-title":"Diabetes Care"},{"issue":"4","key":"692_CR8","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/j.jpain.2016.01.382","volume":"17","author":"K Brown","year":"2016","unstructured":"Brown K, Ohwada S, Warren V, Zahir H, Dishy V. (405) A single ascending-dose study of mirogabalin in healthy subjects: safety, tolerability, pharmacokinetic, and pharmacodynamic results. J Pain. 2016;17(4):S76. https:\/\/doi.org\/10.1016\/j.jpain.2016.01.382 .","journal-title":"J Pain."},{"issue":"4","key":"692_CR9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jpainsymman.2004.01.014","volume":"28","author":"CE Argoff","year":"2004","unstructured":"Argoff CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. J Pain Symptom Manage. 2004;28(4):396\u2013411. https:\/\/doi.org\/10.1016\/j.jpainsymman.2004.01.014 .","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"692_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","volume":"113","author":"Robert H. Dworkin","year":"2005","unstructured":"Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al.; IMMPACT. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1\u20132):9\u201319. https:\/\/doi.org\/10.1016\/j.pain.2004.09.012 .","journal-title":"Pain"},{"issue":"2","key":"692_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105\u201321. https:\/\/doi.org\/10.1016\/j.jpain.2007.09.005 .","journal-title":"J Pain."},{"issue":"2","key":"692_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/jcph.584","volume":"56","author":"OQ Yin","year":"2016","unstructured":"Yin OQ, Merante D, Truitt K, Miller R. Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin. J Clin Pharmacol. 2016;56(2):203\u201312. https:\/\/doi.org\/10.1002\/jcph.584 .","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"692_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2337\/diacare.22.5.756","volume":"22","author":"R Marco de","year":"1999","unstructured":"de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes: the Verona Diabetes Study. Diabetes Care. 1999;22(5):756\u201361.","journal-title":"Diabetes Care"},{"issue":"2","key":"692_CR14","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1053\/j.gastro.2003.10.065","volume":"126","author":"HB El-Serag","year":"2004","unstructured":"El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126(2):460\u20138.","journal-title":"Gastroenterology"},{"issue":"5","key":"692_CR15","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/bjc.1994.427","volume":"70","author":"C Vecchia La","year":"1994","unstructured":"La Vecchia C, Negri E, Franceschi S, D\u2019Avanzo B, Boyle P. A case-control study of diabetes mellitus and cancer risk. Br J Cancer. 1994;70(5):950\u20133.","journal-title":"Br J Cancer"},{"issue":"2","key":"692_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(14)70251-0 .","journal-title":"Lancet Neurol."},{"issue":"8","key":"692_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/bjs.1800600817","volume":"60","author":"RN Pugh","year":"1973","unstructured":"Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646\u20139.","journal-title":"Br J Surg"},{"issue":"4","key":"692_CR18","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/hep.1840130428","volume":"13","author":"AM Hoyumpa","year":"1991","unstructured":"Hoyumpa AM, Schenker S. Is glucuronidation truly preserved in patients with liver disease? Hepatology. 1991;13(4):786\u201395.","journal-title":"Hepatology"},{"issue":"5","key":"692_CR19","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/0016-5085(95)90695-9","volume":"108","author":"HS Debinski","year":"1995","unstructured":"Debinski HS, Lee CS, Danks JA, Mackenzie PI, Desmond PV. Localization of uridine 5\u2032-diphosphate-glucuronosyltransferase in human liver injury. Gastroenterology. 1995;108(5):1464\u20139.","journal-title":"Gastroenterology"},{"issue":"2","key":"692_CR20","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0022-3565(24)38249-7","volume":"289","author":"V Furlan","year":"1999","unstructured":"Furlan V, Demirdjian S, Bourdon O, Magdalou J, Taburet AM. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. J Pharmacol Exp Ther. 1999;289(2):1169\u201375.","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"692_CR21","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147\u201361. https:\/\/doi.org\/10.1007\/s00228-008-0553-z .","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-018-0692-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0692-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0692-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T18:33:51Z","timestamp":1751826831000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-018-0692-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["692"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0692-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,31]]},"assertion":[{"value":"31 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Daiichi Sankyo, Inc., Basking Ridge, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Thomas Marbury reports grants from the Orlando Clinical Research Center during the conduct of the study and is an equity owner of the Orlando Clinical Research Center. Giorgio Senaldi, Vance Warren, and Hamim Zahir were employees of Daiichi Sankyo at the time the study was conducted. Kenneth Duchin is a consultant to Daiichi Sankyo and has no other\u00a0conflicts of interest to report. Kenneth Lasseter has no conflicts of interest that are directly relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects provided written informed consent prior to enrollment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}